CoChat

One‐year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment

Kothny, W., Shao, Q., Groop, P.‐H., Lukashevich, V. · 2012 · Diabetes, Obesity and Metabolism
Cited by 104

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Aim: Assess long‐term safety and efficacy of the dipeptidlyl peptidase-4 (DPP ‐4) inhibitor vildagliptin in 369 patients with type 2 diabetes mellitus ( T2DM ) and moderate or severe renal impairment ( RI ). Methods: Double‐blind, randomized, parallel‐group, 52‐week clinical trial comparing safety and efficacy of vildagliptin (50 mg qd, n = 216) and placebo (n = 153) added to ongoing stable antihyperglycaemic treatment, in patients with T2DM and moderate or severe (glomerular filtration rate [ GFR ] ≥30 to <50 ml/min/1.73 m 2 and < 30 ml/min/1.73 m 2 ) RI . Results: The study population comprised 122 and 89 patients with moderate RI and 94 and 64 patients with severe RI randomized to vildagliptin and placebo, respectively, with the majority of patients receiving background insulin therapy (72% and 82% for moderate and severe RI , respectively). After 1 year, the between‐treatment difference in adjusted mean change in A1C was −0.4 ± 0.2% (p = 0.005) in moderate RI (baseline = 7.8%) and −0.7 ± 0.2% (p < 0.0001) in severe RI (baseline = 7.6%). In patients with moderate RI , similar proportions of patients experienced any adverse event ( AE ) (84 vs. 85%), any serious adverse event ( SAE ) (21 vs. 19%), any AE leading to discontinuation (5% vs. 6%) and death (1% vs. 0%) with vildagliptin and placebo, respectively. This was also true for patients with severe RI : AEs (85% vs. 88%), SAEs (25% vs. 25%), AEs leading to discontinuation (10% vs. 6%) and death (3% vs. 2%). Conclusions: In patients with T2DM and moderate or severe RI , vildagliptin added to ongoing antidiabetic therapy had a safety profile similar to placebo during 1‐year observation. Furthermore, relative to placebo, a clinically significant decrease in A1C was maintained throughout 1‐year treatment with vildagliptin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2012.01634.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 104

Metadata

Authors
Kothny, W., Shao, Q., Groop, P. ‐., & Lukashevich, V.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2012-07-08
Volume
14
Issue
11
Pages
1032-1039
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2154277743
Cited by
104
References
4
FWCI
12.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.